Bexarotene/betamethasone dipropionate

Drug Profile

Bexarotene/betamethasone dipropionate

Alternative Names: Betamethasone dipropionate/bexarotene; LAS 41004

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall S.A.
  • Class Anti-inflammatories; Antipsoriatics; Benzoic acids; Fluorinated steroids; Glucocorticoids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoid X receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 13 Oct 2014 Almirall completes a phase IIa trial in Plaque psoriasis in Germany (EudraCT2013-003757-22)
  • 21 Aug 2014 Almirall completes a phase I/II trial in Plaque psoriasis in Germany (NCT02111499)
  • 05 May 2014 Almirall initiates enrolment in a phase IIa trial for Plaque psoriasis in Germany (EudraCT2013-003757-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top